MiMedx Group, Inc. (NASDAQ:MDXG) Given Average Rating of “Buy” by Brokerages

MiMedx Group, Inc. (NASDAQ:MDXG) has received an average rating of “Buy” from the four ratings firms that are presently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued a report on the stock in the last year is $12.25.

A number of equities analysts have recently issued reports on the stock. Lake Street Capital began coverage on shares of MiMedx Group in a research report on Thursday, March 7th. They set a “buy” rating and a $12.00 target price on the stock. Mizuho lifted their target price on shares of MiMedx Group from $13.00 to $14.00 and gave the company a “buy” rating in a report on Friday, March 1st.

MiMedx Group Stock Down 2.9 %

MiMedx Group stock opened at $6.25 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.11 and a current ratio of 3.57. The firm has a 50 day moving average price of $7.50 and a 200 day moving average price of $7.56. MiMedx Group has a fifty-two week low of $3.49 and a fifty-two week high of $9.27. The company has a market capitalization of $917.77 million, a PE ratio of 19.52 and a beta of 1.32.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). MiMedx Group had a net margin of 14.49% and a return on equity of 41.12%. The business had revenue of $86.83 million during the quarter, compared to analysts’ expectations of $85.58 million. Research analysts expect that MiMedx Group will post 0.33 earnings per share for the current year.

Insider Transactions at MiMedx Group

In related news, CAO William Frank Iv Hulse sold 20,381 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $7.95, for a total transaction of $162,028.95. Following the transaction, the chief accounting officer now directly owns 479,959 shares of the company’s stock, valued at approximately $3,815,674.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CAO William Frank Iv Hulse sold 20,381 shares of the stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total transaction of $162,028.95. Following the transaction, the chief accounting officer now owns 479,959 shares of the company’s stock, valued at $3,815,674.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Ricci S. Whitlow sold 15,271 shares of MiMedx Group stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total value of $122,320.71. Following the completion of the transaction, the chief operating officer now owns 401,050 shares of the company’s stock, valued at approximately $3,212,410.50. The disclosure for this sale can be found here. Insiders sold 51,145 shares of company stock valued at $409,378 over the last 90 days. Corporate insiders own 19.90% of the company’s stock.

Institutional Investors Weigh In On MiMedx Group

A number of hedge funds have recently made changes to their positions in MDXG. Vanguard Group Inc. lifted its holdings in MiMedx Group by 4.1% in the third quarter. Vanguard Group Inc. now owns 6,437,155 shares of the company’s stock worth $46,927,000 after purchasing an additional 250,812 shares during the period. Cannell Capital LLC lifted its stake in shares of MiMedx Group by 9.1% in the 4th quarter. Cannell Capital LLC now owns 2,480,969 shares of the company’s stock worth $21,758,000 after acquiring an additional 207,207 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of MiMedx Group by 5.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,134,213 shares of the company’s stock valued at $9,947,000 after acquiring an additional 57,704 shares in the last quarter. EAM Investors LLC increased its stake in shares of MiMedx Group by 20.9% during the third quarter. EAM Investors LLC now owns 664,213 shares of the company’s stock valued at $4,842,000 after acquiring an additional 114,880 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in MiMedx Group by 1,577.5% during the fourth quarter. Russell Investments Group Ltd. now owns 525,059 shares of the company’s stock worth $4,605,000 after purchasing an additional 493,759 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.